Background: In incident hemodialysis (HD) patients, the relationship between early systolic blood pressure (SBP) dynamics and mortality is unknown. Methods: Baseline SBP levels were stratified into 5 categories ranging from <120 and ≥180 mm Hg. Early pre-HD SBP change was defined as the slope of pre-HD SBP from week 1 to 12 and categorized in quartiles (Q1, lowest slope). SBP slopes were computed for each patient by simple linear regression. Results: In 3,446 incident HD patients (42% females, 44% black, age 62 ± 15 years), the median pre-HD SBP slope was –1.7 (Q1) to +2.3 (Q4) mm Hg/week. In an adjusted multivariate Cox regression analysis, patients with declining SBP (slope Q1) had higher mortality compared to patients with increasing pre-HD SBP (slope Q4) at 12 months (hazard ratio 2.01, 95% confidence interval 1.35–3.01). In addition, patients with baseline pre-HD SBP <120 mm Hg showed higher mortality compared to the reference group (SBP ≥180 mm Hg) at 12 months (hazard ratio 1.89, 95% confidence interval 1.03–3.45). Conclusion: Baseline pre-HD SBP and early SBP dynamics are associated with mortality in the first year of dialysis. Patients who had low (pre-HD SBP <120 mm Hg) or declining SBP had the highest mortality rates. Particular attention is warranted in incident HD patients with low or declining SBP.

Keywords:
Hemodialysis, Mortality, Systolic blood pressure
1.
Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al: CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(suppl 2):S13.
2.
Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598–615.
3.
Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003;115:291–297.
4.
Kotanko P: Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif 2006;24:95–99.
5.
Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, et al: Blood pressure in chronic kidney disease stage 5D – report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2010;77:273–284.
6.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
7.
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45:S1–S153.
8.
Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al: ‘U’ curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998;54:561–569.
9.
Stidley CA, Hunt WC, Tentori F, Schmidt D, Rohrscheib M, Paine S, et al: Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006;17:513–520.
10.
Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, et al: The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006;48:606–615.
11.
Raimann J, Usvyat LA, Thijssen S, Kotanko P, Rogus J, Lacson E Jr, Levin NW: Blood pressure stability in hemodialysis patients confers a survival advantage: results from a large retrospective cohort study. Kidney Int 2012;8:548–558.
12.
Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al: Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010;55:S1–S420, A6–A7.
13.
Mailloux LU, Bellucci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA: Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol 1994;42:127–135.
14.
Eisenstein EL, Sun JL, Anstrom KJ, Stafford JA, Szczech LA, Muhlbaier LH, et al: Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009;122:170–180.
15.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010–2019.
16.
Goldwasser P, Mittman N, Antignani A, Burrell D, Michel MA, Collier J, et al: Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993;3:1613–1622.
17.
Myers OB, Adams C, Rohrscheib MR, Servilla KS, Miskulin D, Bedrick EJ, et al: Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol 2010;21:1970–1978.
18.
Mazzuchi N, Carbonell E, Fernandez-Cean J: Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000;58:2147–2154.
19.
McIntyre CW: Haemodialysis-induced myocardial stunning in chronic kidney disease – a new aspect of cardiovascular disease. Blood Purif 2010;29:105–110.
20.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009;4:914–920.
21.
Jefferies HJ, Virk B, Doss S, Sun S, John SG: Frequent hemodialysis regimens are associated with reduction in dialysis-induced myocardial stunning and systemic inflammation (abstract). J Am Soc Nephrol 2009;20:439A.
22.
Agarwal R, Peixoto AJ, Santos SF, et al: Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit 2009;14:2–11.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.